Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meiqing Wu

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
Annals of Hematology|March 3, 2026
Transforming the treatment of Alpha-Thalassemia: a single-center retrospective study on hematopoietic stem cell transplantation in transfusion-dependent pediatric patientsLihua Huang, Zhenbin Wei, Gaohui Yang, et al.
JAMA Network Open|July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and OutcomesSijian Yu, Zhiping Fan, Liping Ma, et al.
Nature Communications|February 23, 2026
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemiaRongrong Liu, Hongwen Xiao, Chunjie Qin, et al.
Leukemia|May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trialYu Zhang, Zinan Feng, Jing Du, et al.
Experimental Hematology & Oncology|July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative studySijian Yu, Hui Liu, Weihua Zhao, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
Annals of Hematology|March 3, 2026
Transforming the treatment of Alpha-Thalassemia: a single-center retrospective study on hematopoietic stem cell transplantation in transfusion-dependent pediatric patientsLihua Huang, Zhenbin Wei, Gaohui Yang, et al.
JAMA Network Open|July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and OutcomesSijian Yu, Zhiping Fan, Liping Ma, et al.
Nature Communications|February 23, 2026
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemiaRongrong Liu, Hongwen Xiao, Chunjie Qin, et al.
Leukemia|May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trialYu Zhang, Zinan Feng, Jing Du, et al.
Experimental Hematology & Oncology|July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative studySijian Yu, Hui Liu, Weihua Zhao, et al.
Pageof 4